Rabbit p27 Polyclonal Antibody | anti-p27 antibody

p27 Polyclonal Antibody

Cat. Num. AAA2556090

• Gene Names: CDKN1B; KIP1; MEN4; CDKN4; MEN1B; P27KIP1
• Reactivity: Human, Mouse, Rat
• Applications: Immunohistochemistry
• Purity: Affinity Purification
• Synonyms: p27; Polyclonal Antibody; p27 Polyclonal Antibody; AA408329; AI843786; Cdki1b; CDKN 1B; CDKN 4; CDKN1B; CDKN4; CDN1B; Cyclin Dependent Kinase Inhibitor 1B; Cyclin dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor 1B (p27; Kip1); Cyclin-dependent kinase inhibitor 1B; Cyclin-dependent kinase inhibitor p27; Cyclin-dependent kinase inhibitor p27 Kip1; KIP 1; KIP1; MEN1B; MEN4; OTTHUMP00000195098; OTTHUMP00000195099; p27 Kip1; P27-like cyclin-dependent kinase inhibitor; p27Kip1; anti-p27 antibody

• Host: Rabbit
• Reactivity: Human, Mouse, Rat
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Affinity Purification
• Form/Format: PBS with 0.02% sodium azide, 100 mug/ml BSA and 50% glycerol.
• Concentration: 0.89 mg/mL (varies by lot)
• Sequence Length: 198

• Applicable Applications for anti-p27 antibody: Immunohistochemistry (IHC)
• Application Notes: IHC: 1:400
• Immunogen: KLH conjugated synthetic peptide corresponding to Mouse P27 KIP1
• Conjugation: Unconjugated
• Preparation and Storage: Store at -20 degree C. Avoid freeze/thaw cycles.

Immunohistochemistry (IHC)

(Immunohistochemistry analysis of paraffin-embedded human lung cancer using p27 Polyclonal Antibody at dilution of 1:200.)

Immunohistochemistry (IHC)

(Immunohistochemistry analysis of paraffin-embedded human liver cancer using p27 Polyclonal Antibody at dilution of 1:200.)

Immunohistochemistry (IHC)

(Immunohistochemistry analysis of paraffin-embedded Rat spleen cancer using p27 Polyclonal Antibody at dilution of 1:200.)

Related Product Information for anti-p27 antibody

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4).

Product Categories/Family for anti-p27 antibody

Cancer; Cell Biology; Epigenetics and Nuclear Signaling

NCBI and Uniprot Product Information

• NCBI GI #: 4757962
• NCBI GeneID: 1027
• NCBI Accession #: NP_004055.1
• NCBI GenBank Nucleotide #: NM_004064.4
• UniProt Accession #: P46527; Q16307; Q5U0H2; Q9BUS6
• Molecular Weight: 22,073 Da
• NCBI Official Full Name: cyclin-dependent kinase inhibitor 1B
• NCBI Official Synonym Full Names: cyclin dependent kinase inhibitor 1B
• NCBI Official Symbol: CDKN1B
• NCBI Official Synonym Symbols: KIP1; MEN4; CDKN4; MEN1B; P27KIP1
• NCBI Protein Information: cyclin-dependent kinase inhibitor 1B
• UniProt Protein Name: Cyclin-dependent kinase inhibitor 1B
• Protein Family: IAP-like protein
• UniProt Gene Name: CDKN1B
• UniProt Synonym Gene Names: KIP1

NCBI Description

This gene encodes a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. The encoded protein binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controls the cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Mutations in this gene are associated with multiple endocrine neoplasia type IV (MEN4). [provided by RefSeq, Apr 2014]

Uniprot Description

Important regulator of cell cycle progression. Inhibits the kinase activity of CDK2 bound to cyclin A, but has little inhibitory activity on CDK2 bound to SPDYA (PubMed:28666995). Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry.